Author:
Krishnamoorthy Sneha,Periyasamy Loganayaki,Jayapradha G.,Sabanayagam Rajalakshmi,Elango Hemnath,Vishwanathan M.,Muthusami Sridhar
Reference106 articles.
1. Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism;Abourehab;Molecules,2021
2. Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?;Bergonzini;Expert Opin. Pharmacother.,2020
3. Acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer: how do we overcome it?;Bertoli;Int. J. Mol. Sci.,2022
4. EGFR ligands dictate tumour suppression;Beytagh;Nat. Cell Biol.,2022
5. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study;Cascone;ESMO Open,2021